Jade Biosciences (JBIO) Share-based Compensation (2020 - 2026)

Jade Biosciences has reported Share-based Compensation for 7 years, with the latest figure at $7.4 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 205.61% year-over-year to $7.4 million; the trailing twelve-month figure through Mar 2026 stood at $25.0 million (up 230.09% YoY), and the FY2025 full-year result was $20.0 million, up 76.9% from the prior year.
• Share-based Compensation for Q1 2026 stood at $7.4 million, down from $9.4 million in the prior quarter.
• The five-year high for Share-based Compensation was $9.4 million in Q4 2025, with the low at $27000.0 in Q3 2024.
• Historically, Share-based Compensation has averaged $3.2 million across 5 years, with a median of $3.0 million in 2023.
• Annual changes were most pronounced in 2024 — Share-based Compensation slumped 99.17% — and 2025, when it jumped 15807.41%.
• Jade Biosciences' Share-based Compensation stood at $1.7 million in 2022, then soared by 88.03% to $3.3 million in 2023, then plunged by 61.37% to $1.3 million in 2024, then jumped by 648.09% to $9.4 million in 2025, then dropped by 21.19% to $7.4 million in 2026.
• The last three Share-based Compensation figures came in at $7.4 million (Q1 2026), $9.4 million (Q4 2025), and $4.3 million (Q3 2025), per Business Quant data.